The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.05 (1.52%)
Spread: 0.10 (3.03%)
Open: 3.30
High: 3.35
Low: 3.30
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Aug 2020 14:49

RNS Number : 9761U
ValiRx PLC
03 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Valirx PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Monecor (London) Limited

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

31/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

6.413

-

6.413

54,062,373

Position of previous notification (if

applicable)

8.86

8.86

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00BLH13C52

 

3,466,989

-

6.413

-

SUBTOTAL 8. A

3,466,989

6.413

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

03/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUOSORRWUWRAR
Date   Source Headline
5th Feb 20157:00 amRNSAcquisition
15th Jan 20157:00 amRNSClinical Trial and Development Update
18th Dec 20147:00 amRNSIssue of Equity
4th Dec 20147:00 amRNSValiSeek Scientific Update
26th Nov 20147:00 amRNSRe: Progress with Trial Recruitment and Testing
13th Nov 20147:00 amRNSCollaboration Agreement
7th Nov 201410:23 amRNSHolding(s) in Company
3rd Nov 201411:00 amRNSApproved Clinical Trial Update
31st Oct 20147:00 amRNSTotal Voting Rights
23rd Oct 201410:45 amRNSGrant of options
14th Oct 20147:00 amRNSApproved Clinical Trial Update
8th Oct 20144:12 pmRNSEarly Completion of Equity Swap Agreement
8th Oct 20144:08 pmRNSHolding(s) in Company
2nd Sep 20147:00 amRNSValiSeek Development Update
28th Aug 201411:33 amRNSHolding(s) in Company
19th Aug 20147:00 amRNSHalf Yearly Report
5th Aug 201412:05 pmRNSHolding(s) in Company
4th Aug 20147:00 amRNSNotice of Acceptance of CTA Request
1st Jul 201411:35 amRNSHolding(s) in Company
24th Jun 20147:00 amRNSDirector/PDMR Shareholding
18th Jun 20149:22 amRNSNew Corporate Website & New Office Address
10th Jun 20147:00 amRNSSubmission of Clinical Trial Application re VAL201
15th May 20147:00 amRNSValiSeek Development Update
1st May 20147:00 amRNSNew Japanese Patent Grant
23rd Apr 20144:29 pmRNSResult of AGM
17th Apr 20145:51 pmRNSHolding(s) in Company
8th Apr 20147:00 amRNSValiSeek Joint Venture
1st Apr 20147:00 amRNSVAL201 Update
31st Mar 20144:45 pmRNSNotice of AGM
31st Mar 20144:09 pmRNSHolding(s) in Company
28th Mar 20147:01 amRNSPosting of R&As and Notice of AGM
19th Mar 20147:00 amRNSFinal Results
20th Feb 20147:00 amRNSNew European Patent Grant
31st Jan 201412:45 pmRNSSale of shares in VolitionRx
22nd Jan 20143:00 pmRNSGrant of Options
16th Jan 20147:00 amRNSIssue of Equity
27th Dec 20137:00 amRNSFundraising and Equity Swap
5th Dec 20137:00 amRNSNew Australian Patent Grant
28th Nov 20137:00 amRNSUpdate re Positive VAL201 & Biomarker Unit Studies
15th Nov 20137:00 amRNSPlacing to raise £1m
1st Nov 20137:00 amRNSChange of Broker
24th Oct 20134:25 pmRNSRe: VAL201 - Update
8th Oct 20137:00 amRNSDirectorate Changes
5th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSConsortium incl. ValiRx Awarded Eurostars Grant
31st Jul 20137:00 amRNSUpdate
25th Jun 20137:00 amRNSInvestor Presentation in Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
13th Jun 20137:00 amRNSRe: VAL201 Update
6th Jun 201310:00 amRNSValiRx admitted as founder member of the SSE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.